Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized Surfactant for RDS in Premature Infants
NCT02825953Unknown
- Start
- Jan 2016
- Primary completion
- Jan 2017
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Randomised, open-label trial of Poractant alfa in neonatal respiratory distress syndrome (NRDS) (3 arms). Primary endpoints: Safety of surfactant nebulization at 72 hours and Need for mechanical ventilation at 72 hours. Status: unknown.
02
Drugs
Poractant alfa
03
Conditions
neonatal respiratory distress syndrome (NRDS)
Beyond the preview
Go deeper on NCT02825953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02825953.